About Cdc42 effector protein 1
Cdc42 effector protein 1 (CDC42EP1) is a protein
from Homo sapiens identified by UniProt accession
Q00587, 391 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Cdc42 effector protein 1 |
|---|
| UniProt accession | Q00587 |
|---|
| Gene | CDC42EP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 391 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (21)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.26
- Parkinson disease · score 0.26
- lysosomal storage disease · score 0.26
- neurodegenerative disease · score 0.26
- Alzheimer disease · score 0.26
- creatinine measurement · score 0.15
- blood protein measurement · score 0.12
- breast carcinoma · score 0.03
- Sepsis · score 0.02
- oral squamous cell carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q00587-F1 | alphafold | PREDICTED | 54.19 | — |
Amino-acid sequence (391 residues)
MPGPQGGRGA ATMSLGKLSP VGWVSSSQGK RRLTADMISH PLGDFRHTMH VGRGGDVFGD TSFLSNHGGS SGSTHRSPRS FLAKKLQLVR RVGAPPRRMA SPPAPSPAPP AISPIIKNAI SLPQLNQAAY DSLVVGKLSF DSSPTSSTDG HSSYGLDSGF CTISRLPRSE KPHDRDRDGS FPSEPGLRRS DSLLSFRLDL DLGPSLLSEL LGVMSLPEAP AAETPAPAAN PPAPTANPTG PAANPPATTA NPPAPAANPS APAATPTGPA ANPPAPAASS TPHGHCPNGV TAGLGPVAEV KSSPVGGGPR GPAGPALGRH WGAGWDGGHH YPEMDARQER VEVLPQARAS WESLDEEWRA PQAGSRTPVP STVQANTFEF ADAEEDDEVK V
Explore Cdc42 effector protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets